Navigation Links
Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs
Date:7/22/2009

. There is an urgent need for medication that can do more than simply cloak the effects of this disease."

Continuing Innovation Critical

When it moves to the new East River Science Park, which is expected to open sometime in the summer of 2010, ImClone will have access to a state-of-the-art facility for conducting its innovative research. ImClone's Research group conducts the preclinical discovery efforts that have produced the clinical product candidates in ImClone's robust pipeline of therapeutic antibodies. The new location will help expand collaborative activities with local academic institutions as ImClone further accelerates its research to add new molecules to its pipeline. In addition to the second Phase III trial of IMC-1121B announced today, ImClone has made several advancements in its pipeline since being acquired by Lilly. Highlights include:

  • IMC-11F8 is expected to move into Phase III development by the end of 2009;
  • Phase II testing of IMC-A12 has been expanded to include colorectal, neuroendocrine and lung cancers. Phase III studies of IMC-A12 are expected to begin in either late 2009 or early 2010;
  • IMC-3G3 has recently moved into Phase II development with a study in ovarian cancer, and additional Phase II studies in other tumor types are planned;
  • Phase II studies of IMC-1121B have been expanded to include colorectal cancer;
  • The first Phase I trial of IMC-EB10, in leukemia, was recently launched, increasing the number of ImClone molecules in clinical development to six; and
  • ImClone also expects to file at least one new investigational new drug (IND) application by the end of 2009.

According to Lilly Chairman, President and CEO John Lechleiter, Ph.D., "Having six monoclonal antibodies contributed by ImClone to the Lilly oncology portfolio is a great step toward achievement o
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... 16 Cellular Dynamics International ... of iCell(TM) Cardiomyocytes for use in testing of ... These human heart cells are designed to aid ... compound efficacy and toxicity screens, weeding out ineffective ... pipeline process before significant time and resources have ...
(Date:12/15/2009)... ZURICH, Ill., Dec. 15 Fenwal Inc., a ... availability for patient care, reiterated its commitment to provide ... lifesaving blood products, despite a new lawsuit filed yesterday ... Fenwal® Alyx® system, introduced in 2003, is an advanced ... red cells from a single donor in about 30 ...
(Date:12/15/2009)... Robbins & Myers, Inc. (NYSE: ... for its fiscal 2010 first quarter ending November 30, ... 2010. A live webcast is scheduled for ... Peter C. Wallace, President and Chief Executive ... Financial Officer, will be discussing the Company,s performance and ...
Breaking Medicine Technology:Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 2Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 3Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 4Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers 2Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers 3Personality predicts success in medical school says new study by U of Minnesota professor 62539 1Personality predicts success in medical school says new study by U of Minnesota professor 62539 2Species down disease up 10986 1Species down disease up 10986 2Species down disease up 10986 3Species down disease up 10986 4Stopping MRSA before it becomes dangerous is possible Sandia UNM researchers find 10982 1Stopping MRSA before it becomes dangerous is possible Sandia UNM researchers find 10982 2Stopping MRSA before it becomes dangerous is possible Sandia UNM researchers find 10982 3
... S.A. (Euronext,Paris: COX) today announced that Pfizer Inc (NYSE: ... study for PF-03187207 in Japan. PF-03187207,is a new experimental ... an ongoing phase 2 proof-of-concept study in the United ... Glaucoma and ocular,hypertension are a group of severe eye ...
... First Molecular Test to Simultaneously Identify Staphylococcus aureus ... Cultures, SAN DIEGO, Jan. 2 BD ... (NYSE: BDX ), announced today that it,received ... (FDA) for the,BD GeneOhm(TM) StaphSR assay. This new ...
Other Medicine Technology:NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan 2NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan 3BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures 2BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures 3
(Date:12/15/2009)... Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the research, development ... had approved all three resolutions that the Company had proposed at the Annual General Meeting ... Description of ... Votes Non-, ... For Against ...
(Date:12/15/2009)... Lady of Lourdes Health Care Services Inc., the parent ... pay the United States $7.95 million to resolve allegations ... today. The two hospitals are Our Lady of Lourdes ... Center of Burlington County (LMC) in Willingboro, N.J. ... by a whistleblower, Tony Kite, in 2005. The lawsuit ...
(Date:12/15/2009)... 800,000 doses have lower strength than needed for protection, ... Almost 800,000 children,s doses of H1N1 swine flu vaccine ... they have lost some potency, federal health officials said ... Control and Prevention, the company,s routine testing of the ... years found that four batches had lower than required ...
(Date:12/15/2009)... Systems, Inc., a leading provider of advanced inventory ... increase profits by optimizing their inventory and related ... Shoppe has been utilizing the 4R solution since ... solutions have helped us drive significant improvements in ... two years," said Tony Truesdale, President & Chief ...
(Date:12/15/2009)... BRAINTREE, Mass., Dec. 15 North American ... +3.9% in November year-over-year, according to the ... life insurance applications over the past three months ... 2009 levels of -1.6%, to flat at November,s ... recovering their interest in the benefits available from ...
Breaking Medicine News(10 mins):Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2Health News:Large Recall of Children's Swine Flu Vaccine 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 3Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 4Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 2Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 3
... scientific journal regarding a plausible adverse reaction of a ... human participants, which turned awry triggering a severe drug ... participants would have been history. ,A ... the trial, blamed gross negligence to clear warnings of ...
... of poultry, eggs and related products from India two months ... imposed an indefinite ban on the import of poultry and ... virus in poultry in India's Maharashtra state. On Aug 12, ... led to the culling of millions of infected poultry across ...
... aged 50 years old, who hailed from Edinburgh, had died ... skins. // Scrutiny by the NHS revealed that the spores ... attended classes. The spores were present in three drums and ... ,It is estimated that 174 persons in the least ...
... Children’s Hospital Medical Center today announced the publication of ... mechanism of action of the protein RhoH GTPase in ... immune system. The findings, along with other studies, suggest ... intervention in some types of leukemia. ...
... Research Hospital turned up the heat on “disorderly” proteins ... perform critical functions in the cell. The St. Jude ... of these so-called intrinsically unstructured proteins (IUPs), a large ... daily activities of cells. ,The new technique for ...
... The need for more awake surgery was made at a ... Irish Cancer Society. // , ,According to the ... time-consuming and expensive, it has higher rate of success and ... Cancer Registry’s recent data reveal that there were 316 new ...
Other Medicine News:Health News:Bhutan Lifts Ban on Poultry from India 2Health News:Potential Target for Leukemia Treatment 2Health News:First Major Study of Mammalian “Disorderly” Protei 2Health News:Awake Surgery to treat Brain tumours 2
2L...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
5L...
Medicine Products: